Search results for "arki"

showing 10 items of 1015 documents

Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson’s disease

2003

Increased echogenicity of the substantia nigra (SN) on ultrasound is a typical sonographic finding in Parkinson's disease (PD). Sonographic signal intensity of the SN is related to tissue iron content with higher iron level being associated with increased echogenicity. Recent findings indicate that hyperechogenicity of the SN represents an important susceptibility factor for nigrostriatal degeneration. In this study we determined the prevalence of a characteristic ultrasound sign of Parkinson's disease in first-degree relatives of PD patients. Fourteen patients with sporadic PD and 58 of their relatives underwent neurological, neuropsychological, and ultrasound examination. In addition, fou…

AdultMaleFluorine RadioisotopesPathologymedicine.medical_specialtyParkinson's diseaseUltrasonography Doppler TranscranialCognitive NeuroscienceSubstantia nigraNeuropsychological TestsHypokinesiamedicineHumansGenetic Predisposition to DiseaseGenetic TestingDominance CerebralProblem SolvingDominance (genetics)business.industryPutamenUltrasoundEchogenicityParkinson DiseaseMiddle Agedmedicine.diseaseDihydroxyphenylalanineTranscranial DopplerSubstantia NigraNeurologyNerve DegenerationFemalemedicine.symptomPsychologybusinessTomography Emission-ComputedNeuroImage
researchProduct

Effects of levodopa oral bolus on the kinematics of the pointing movements in Parkinson's disease patients.

2005

We studied the time-course of a levodopa oral bolus effects on the kinematics of patients affected by a mild akinetic-rigid form of idiopathic Parkinson's disease (PD). Eleven PD patients were evaluated: a) in OFF-state, that is before their first medication or after its withdrawal, b) in ON-state, that is at 1/2, 1, 2, 3, 4, 5, 6, 24, 30 and 48 hours after the administration of 250 mg of levodopa plus 25mg of carbidopa. The main kinematics (i. e.movement time, peak of velocity, peak of acceleration and peak of deceleration) of pointing movements to six target-stimuli placed on the horizontal plane of a table were recorded. Clinical conditions were assessed according to the Motor Examinatio…

AdultMaleLevodopamedicine.medical_specialtyTime FactorsNeurologyParkinson's diseaseAdministration Oralparkinson's diesease clinical neurophysiology kinematicsKinematicsClinical neurophysiologyAntiparkinson AgentsLevodopaCentral nervous system diseaseBolus (medicine)Internal medicinemedicineHumansAgedbusiness.industryParkinson DiseaseMiddle Agedmedicine.diseaseBiomechanical PhenomenaSurgeryNeurologyCarbidopaCardiologyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessPsychomotor Performancemedicine.drug
researchProduct

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET

2009

Abstract Transcranial ultrasound (TCS) has been shown to reveal hyperechogenicity of the substantia nigra (SN) in Parkinsonian patients and in about 10% of healthy controls. It is hypothesized that SN hyperechogenicity in healthy subjects is a vulnerability marker for idiopathic Parkinson's disease (IPD). Although there is strong evidence that the echomarker results from increased local iron content, the exact pathophysiological mechanisms remain incompletely understood. Thus, prognostic impact can only be estimated. We examined 14 subjects with SN hyperechogenicity (SN+) (7 IPD patients and 7 controls) and 7 healthy controls without the echomarker (SN−) by a magnetic resonance imaging meth…

AdultMalePathologymedicine.medical_specialtyCognitive NeuroscienceSubstantia nigraReference ValuesmedicineHumansNeuronsmedicine.diagnostic_testbusiness.industryTissue inhomogeneityHealthy subjectsParkinson DiseaseMagnetic resonance imagingMiddle AgedEchoencephalographyMagnetic Resonance ImagingPathophysiologyDihydroxyphenylalanineTranscranial DopplerSubstantia NigraNeurologyPositron-Emission TomographyT2 relaxationIron contentFemaleRadiopharmaceuticalsbusinessNeuroImage
researchProduct

Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily.

2007

Abstract Objective To estimate prevalence of Parkinson's disease (PD) and other types of parkinsonism in the Aeolian Archipelago, Sicily. Methods We studied the frequency of PD and other types of parkinsonism in the Aeolian Archipelago (population 13,431). All potential cases were identified from available medical information sources. To ensure the completeness of the case-findings, a screening questionnaire was also mailed to residents aged 40 years and over. Subjects were considered prevalent if they fulfilled the SNES diagnostic criteria for PD, on prevalence day (January 1, 2001). Results We identified 17 patients with parkinsonism from medical sources, and 4 from mail-survey. Prevalenc…

AdultMalePediatricsmedicine.medical_specialtyParkinson's diseasePopulationMedical informationDiseaseSeverity of Illness IndexParkinsonian DisordersEpidemiologyEpidemiology parkinsonism prevalencemedicineHumanseducationSicilyAeolian archipelagoAgedAged 80 and overeducation.field_of_studybusiness.industryParkinsonismParkinson DiseaseMiddle Agedmedicine.diseaseHealth SurveysScreening questionnaireNeurologyPhysical therapyFemaleNeurology (clinical)Geriatrics and GerontologybusinessParkinsonismrelated disorders
researchProduct

Motor abnormalities and basal ganglia in first-episode psychosis (FEP)

2020

AbstractBackgroundMotor abnormalities (MAs) are the primary manifestations of schizophrenia. However, the extent to which MAs are related to alterations of subcortical structures remains understudied.MethodsWe aimed to investigate the associations of MAs and basal ganglia abnormalities in first-episode psychosis (FEP) and healthy controls. Magnetic resonance imaging was performed on 48 right-handed FEP and 23 age-, gender-, handedness-, and educational attainment-matched controls, to obtain basal ganglia shape analysis, diffusion tensor imaging techniques (fractional anisotropy and mean diffusivity), and relaxometry (R2*) to estimate iron load. A comprehensive motor battery was applied incl…

AdultMalePsychosismedicine.medical_specialtyAkathisiaBasal Ganglia03 medical and health sciences0302 clinical medicineInternal medicineBasal gangliaFractional anisotropyImage Processing Computer-AssistedmedicineHumansPsychomotor AgitationApplied Psychologymedicine.diagnostic_testbusiness.industryParkinsonismBrainMagnetic resonance imagingmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryMotor coordinationPsychiatry and Mental healthDiffusion Tensor ImagingPsychotic DisordersSchizophreniaCardiologyFemaleAtrophymedicine.symptombusiness030217 neurology & neurosurgeryDiffusion MRIPsychological Medicine
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

Benchmarking of cognitive-behavioral therapy for depression in efficacy and effectiveness studies--how do exclusion criteria affect treatment outcome?

2011

Abstract Objective: Little is known about how exclusion criteria applied in randomized controlled trials (RCTs) affect the transfer of psychotherapy outcome research to naturalistic settings. This study evaluated the effects of naturalistic depression therapies and benchmarked them with published RCTs. Method: Commonly used exclusion criteria were applied to n=338 depressive patients receiving cognitive-behavioral therapy. Outcomes of the resulting subsample eligible for RCTs were compared to those reported in RCTs. Results: Treatment outcomes of the total sample (d=1.16) and the subsample eligible for RCTs (d=1.15) were highly similar. Therapy outcome was worse than in high-quality RCTs (d…

AdultMalePsychotherapistmedicine.medical_treatmentTreatment outcomeAffect (psychology)law.inventionRandomized controlled triallawhealth services administrationmedicineHumansDepression (differential diagnoses)Randomized Controlled Trials as TopicTherapy OutcomeDepressive DisorderCognitive Behavioral TherapyPatient SelectionBenchmarkingCognitive behavioral therapyClinical PsychologyBenchmarkingTreatment OutcomeFemaleDysthymic DisorderPsychologyPsychotherapy research : journal of the Society for Psychotherapy Research
researchProduct

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany

2012

Thomas Glaab1,2, Claus Vogelmeier3, Andreas Hellmann4, Roland Buhl11Department of Respiratory Diseases III, Medical Center of the Johannes Gutenberg-University, Mainz, 2Medical Affairs Germany, Respiratory Medicine, Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, 3Department of Respiratory Diseases, University Hospitals of Giessen and Marburg, Marburg, 4Federal Association of Pneumologists, Augsburg, GermanyBackground: Little is known about the role of guidelines for the practical management of chronic obstructive pulmonary disease (COPD) by office-based pulmonary specialists. The aim of this study was to assess their outpatient management in relation to current guideline recommenda…

AdultMaleSpirometryHealth Knowledge Attitudes Practicemedicine.medical_specialtyChronic bronchitisAttitude of Health Personneldiagnosismedicine.medical_treatmentInternational Journal of Chronic Obstructive Pulmonary DiseasePulmonary Disease Chronic ObstructivePatient Education as TopicAmbulatory careRisk FactorsGermanySurveys and QuestionnairesHealth careAmbulatory CaremedicineHumanssurveyPulmonary rehabilitationGOLDPractice Patterns Physicians'Referral and ConsultationOriginal ResearchtherapyCOPDEvidence-Based Medicinemedicine.diagnostic_testbusiness.industryGeneral MedicineGuidelineMiddle Agedmedicine.diseasepulmonary rehabilitationclinical outcomesObstructive lung diseaseRespiratory Function TestsBenchmarkingCross-Sectional StudiesHealth Care SurveysFamily medicinePractice Guidelines as TopicFemaleGuideline AdherencebusinessInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Urological dysfunctions in patients with Parkinson’s disease: clues from clinical and non-invasive urological assessment

2018

Abstract Background Autonomic nervous system dysfunction, common in patients with Parkinson’s disease (PD), causes significant morbidity and it is correlated with poor quality of life. To assess frequency of urinary symptoms in patients with PD, without conditions known to interfere with urinary function. Methods Non-demented PD patients were consecutively enrolled from the outpatients clinic of our department. Scales investigating motor and non-motor symptoms were carried out. Evaluation of urinary dysfunctions was carried out using the AUTonomic Scale for Outcomes in Parkinson’s disease (SCOPA-AUT) questionnaire. Patients underwent noninvasive urological studies (nUS), including uroflowme…

AdultMaleUrologic Diseasesmedicine.medical_specialtyNeurologyParkinson's diseaseUrinary systemAutonomic dysfunction030232 urology & nephrologyNon-motor symptomsUrinary symptomsDiseaseNon-motor symptomlcsh:RC346-429SCOPA-AUT03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesInternal medicinemedicineHumansNeurochemistryStage (cooking)lcsh:Neurology. Diseases of the nervous systemAgedbusiness.industryAUTonomic SCale for outcomes in Parkinson’s diseaseParkinson DiseaseGeneral MedicineMiddle AgedUrinary functionmedicine.diseaseAutonomic Nervous System DiseasesQuality of LifeParkinson’s diseaseFemaleSettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusiness030217 neurology & neurosurgeryBMC Neurology
researchProduct

Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD.

2001

In 1998, an IL93Met mutation in the ubiquitin carboxy-terminal hydrolase L1 ( UCH-L1 ) gene was identified in a German family affected by PD.1 Recently, others2-4⇓⇓ found that the S18Y polymorphism in exon 3 of UCH-L1 is associated with a low risk of PD. To verify these interesting results, we decided to design a case-control study on the S18Y polymorphism of the UCH-L1 gene using sporadic PD cases. In the meantime, as we were analyzing our samples, a case-control study5 on 142 patients with PD and 142 age- and sex-matched control subjects did not confirm the protective effect found by Maraganore et al.2 In view of these conflicting findings, we reasoned that our contribution may have some …

AdultMaleallele frequenciesParkinson's diseasegenotypepolymorphismlaw.inventionExonDegenerative diseaseUbiquitinlawHydrolasemedicineHumansGeneNeural Cell Adhesion MoleculesPolymerase chain reactionAgedAged 80 and overNeuroscience (all)Membrane GlycoproteinsPolymorphism GeneticbiologyUCH-L1 geneParkinson DiseaseMiddle Agedmedicine.diseaseUbiquitin carboxy-terminal hydrolase L1Settore BIO/18 - GeneticaImmunologybiology.proteinSettore MED/26 - NeurologiaFemaleNeurology (clinical)Gene polymorphismThiolester HydrolasesLeukocyte L1 Antigen ComplexUbiquitin ThiolesteraseNeurology
researchProduct